Regeneron Pharmaceuticals License Agreements
11 Contracts & Agreements
- License Agreement, dated as of August 18, 2020, by and among the Registrant, F. Hoffman-La Roche Ltd, and Genentech, Inc (Filed With SEC on November 5, 2020)
- Praluent Cross License & Commercialization Agreement, dated as of April 5, 2020, and effective as of April 1, 2020, by and between the Registrant and Sanofi Biotechnology SAS (Filed With SEC on August 5, 2020)
- Form of License Agreement (Exhibit C to Master Agreement contained in Exhibit 10.4) (Filed With SEC on August 6, 2019)
- NON-EXCLUSIVE LICENSE AND PARTIALSETTLEMENT AGREEMENT (Filed With SEC on February 21, 2012)
- Amendment to the Non-Exclusive License and Material Transfer Agreement dated as of March 30, 2007 (Filed With SEC on October 28, 2010)
- AMENDED AND RESTATED LICENSE AND COLLABORATIONAGREEMENT By and Among AVENTIS PHARMACEUTICALS INC., SANOFI-AVENTIS AMERIQUE DUNORD and REGENERON PHARMACEUTICALS,INC. Dated as of... (Filed With SEC on February 18, 2010)
- EX-10.2: AMENDED AND RESTATED NON-EXCLUSIVE LICENSE AGREEMENT (Filed With SEC on August 1, 2008)
- EX-10.1: NON-EXCLUSIVE LICENSE AND MATERIAL TRANSFER AGREEMENT (Filed With SEC on May 4, 2007)
- EX-10.14: NON EXCLUSIVE LICENSE AND MATERIAL TRANSFER AGREEMENT (Filed With SEC on March 12, 2007)
- NON-EXCLUSIVE PATENT LICENSE AGREEMENT (Filed With SEC on November 12, 2003)
- LICENSE AGREEMENT (Filed With SEC on August 13, 2002)
